Inovio announced that it has begun the phase 2 segment of a phase2/3 clinical trial to evaluate INO-4800, its potential coronavirus vaccine funded by the Department of Defense.

The phase 2 study, which will enroll 400 participants at 17 U.S. sites, is designed to evaluate the safety, tolerability and immunogenicity of a two-dose regimen.

The phase 3 segment of the trial remains on partial clinical hold until the company resolves the FDA’s questions related to Inovio’s proprietary device that will be used to deliver INO-4800 directly into the skin.